Compare
Starling Oncology, Inc. vs SBC Medical Group Holdings Inc vs Airsculpt Technologies, Inc. vs Hims & Hers Health, Inc.
| Latest fiscal year | Starling Oncology, Inc. STLN | SBC Medical Group Holdings Inc SBC | Airsculpt Technologies, Inc. AIRS | Hims & Hers Health, Inc. HIMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $502.73M | $173.61M | $151.82M | $2.35B |
| Revenue growth (YoY) | +27.8% | -15.5% | -15.8% | +59.0% |
| Gross margin | n/a | 73.3% | n/a | 73.8% |
| Operating margin | -7.2% | 38.9% | -7.6% | 4.5% |
| Net margin | -12.1% | 29.4% | -7.7% | 5.5% |
| Net income | -$60.61M | $50.99M | -$11.67M | $128.37M |
| EPS (Diluted) | -$0.54 | $0.50 | -$0.19 | $0.51 |
| Operating cash flow | -$24.59M | $24.67M | $3.10M | $300.01M |
| Free cash flow | -$27.79M | $23.27M | $692.0K | $57.41M |
| Cash & equivalents | n/a | $163.77M | $8.45M | $228.62M |
| Total assets | $164.66M | $380.45M | $187.30M | $2.15B |
| Total liabilities | $180.38M | $117.14M | $99.59M | $1.61B |
| Shareholders' equity | -$15.72M | $248.28M | $87.71M | $540.93M |
| Return on year-end equity | n/a | 20.5% | -13.3% | 23.7% |
| Shares outstanding | 98.86M | 102.58M | 64.46M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Starling Oncology, Inc. | SBC Medical Group Holdings Inc | Airsculpt Technologies, Inc. | Hims & Hers Health, Inc. |
|---|---|---|---|---|
| Latest | $502.73M Ended 2025-12-31 | $173.61M Ended 2025-12-31 | $151.82M Ended 2025-12-31 | $2.35B Ended 2025-12-31 |
| 1 year earlier | $393.41M Ended 2024-12-31 | $205.42M Ended 2024-12-31 | $180.35M Ended 2024-12-31 | $1.48B Ended 2024-12-31 |
| 2 years earlier | $324.24M Ended 2023-12-31 | $193.54M Ended 2023-12-31 | $195.92M Ended 2023-12-31 | $872.00M Ended 2023-12-31 |
| 3 years earlier | $252.48M Ended 2022-12-31 | n/a | $168.79M Ended 2022-12-31 | $526.92M Ended 2022-12-31 |
| 4 years earlier | $203.00M Ended 2021-12-31 | n/a | $133.31M Ended 2021-12-31 | $271.88M Ended 2021-12-31 |